Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression

Lei L. Chen, Joseph A. Holden, Haesun Choi, Jing Zhu, Elsie F. Wu, Kimberly A. Jones, John H. Ward, Robert H. Andtbacka, R Randall, Courtney L. Scaife, Kelly K. Hunt, Victor G. Prieto, Austin K. Raymond, Wei Zhang, Jonathan C. Trent, Robert S. Benjamin, Marsha L. Frazier

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Activating mutation in KIT or platelet-derived growth factor-α can lead to gastrointestinal stromal tumors (GISTs). Eighty-four cases from two institutes were analyzed. Of them, 62 (74%) harbored KIT mutations, 7 of which are previously unreported. One exhibited duplication from both intron 11 and exon 11, which has not been reported in KIT in human cancer. A homozygous/hemizygous KIT-activating mutation was found in 9 of the 62 cases (15%). We identified three GIST patients with heterozygous KIT-activating mutations at initial presentation, who later recurred with highly aggressive clinical courses. Molecular analysis at recurrence showed total dominance of homozygous (diploid) KIT-activating mutation within a short period of 6-13 months, suggesting an important role of oncogene homozygosity in tumor progression. Topoisomerase II is active in the S- and G2 phases of cell cycle and is a direct and accurate proliferative indicator. Cellular and molecular analysis of serial tumor specimens obtained from consecutive surgeries or biopsy within the same patient revealed that these clones that acquired the homozygous KIT mutation exhibited an increased mitotic count and a striking fourfold increase in topoisomerase II proliferative index (percentage cells show positive topoisomerase II nuclear staining compared to the heterozygous counterpart within the same patient. KIT forms a homodimer as the initial step in signal transduction and this may account for the quadruple increase in proliferation. Using SNPs for allelotyping on the serial tumor specimens, we demonstrate that the mechanism of the second hit resulting in homozygous KIT-activating mutation and loss of heterozygosity is achieved by mitotic nondisjunction, contrary to the commonly reported mechanism of mitotic recombination.

Original languageEnglish (US)
Pages (from-to)826-836
Number of pages11
JournalModern Pathology
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Mutation
Type II DNA Topoisomerase
Neoplasms
Loss of Heterozygosity
G2 Phase
Platelet-Derived Growth Factor
Diploidy
S Phase
Oncogenes
Introns
Genetic Recombination
Single Nucleotide Polymorphism
Exons
Signal Transduction
Cell Cycle
Clone Cells
Staining and Labeling
Biopsy
Recurrence

Keywords

  • GIST
  • Homozygous KIT mutation
  • SNP

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. / Chen, Lei L.; Holden, Joseph A.; Choi, Haesun; Zhu, Jing; Wu, Elsie F.; Jones, Kimberly A.; Ward, John H.; Andtbacka, Robert H.; Randall, R; Scaife, Courtney L.; Hunt, Kelly K.; Prieto, Victor G.; Raymond, Austin K.; Zhang, Wei; Trent, Jonathan C.; Benjamin, Robert S.; Frazier, Marsha L.

In: Modern Pathology, Vol. 21, No. 7, 01.07.2008, p. 826-836.

Research output: Contribution to journalArticle

Chen, LL, Holden, JA, Choi, H, Zhu, J, Wu, EF, Jones, KA, Ward, JH, Andtbacka, RH, Randall, R, Scaife, CL, Hunt, KK, Prieto, VG, Raymond, AK, Zhang, W, Trent, JC, Benjamin, RS & Frazier, ML 2008, 'Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression', Modern Pathology, vol. 21, no. 7, pp. 826-836. https://doi.org/10.1038/modpathol.2008.46
Chen, Lei L. ; Holden, Joseph A. ; Choi, Haesun ; Zhu, Jing ; Wu, Elsie F. ; Jones, Kimberly A. ; Ward, John H. ; Andtbacka, Robert H. ; Randall, R ; Scaife, Courtney L. ; Hunt, Kelly K. ; Prieto, Victor G. ; Raymond, Austin K. ; Zhang, Wei ; Trent, Jonathan C. ; Benjamin, Robert S. ; Frazier, Marsha L. / Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. In: Modern Pathology. 2008 ; Vol. 21, No. 7. pp. 826-836.
@article{66ee761dd69847ecb5cea0f4b06dde84,
title = "Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression",
abstract = "Activating mutation in KIT or platelet-derived growth factor-α can lead to gastrointestinal stromal tumors (GISTs). Eighty-four cases from two institutes were analyzed. Of them, 62 (74{\%}) harbored KIT mutations, 7 of which are previously unreported. One exhibited duplication from both intron 11 and exon 11, which has not been reported in KIT in human cancer. A homozygous/hemizygous KIT-activating mutation was found in 9 of the 62 cases (15{\%}). We identified three GIST patients with heterozygous KIT-activating mutations at initial presentation, who later recurred with highly aggressive clinical courses. Molecular analysis at recurrence showed total dominance of homozygous (diploid) KIT-activating mutation within a short period of 6-13 months, suggesting an important role of oncogene homozygosity in tumor progression. Topoisomerase II is active in the S- and G2 phases of cell cycle and is a direct and accurate proliferative indicator. Cellular and molecular analysis of serial tumor specimens obtained from consecutive surgeries or biopsy within the same patient revealed that these clones that acquired the homozygous KIT mutation exhibited an increased mitotic count and a striking fourfold increase in topoisomerase II proliferative index (percentage cells show positive topoisomerase II nuclear staining compared to the heterozygous counterpart within the same patient. KIT forms a homodimer as the initial step in signal transduction and this may account for the quadruple increase in proliferation. Using SNPs for allelotyping on the serial tumor specimens, we demonstrate that the mechanism of the second hit resulting in homozygous KIT-activating mutation and loss of heterozygosity is achieved by mitotic nondisjunction, contrary to the commonly reported mechanism of mitotic recombination.",
keywords = "GIST, Homozygous KIT mutation, SNP",
author = "Chen, {Lei L.} and Holden, {Joseph A.} and Haesun Choi and Jing Zhu and Wu, {Elsie F.} and Jones, {Kimberly A.} and Ward, {John H.} and Andtbacka, {Robert H.} and R Randall and Scaife, {Courtney L.} and Hunt, {Kelly K.} and Prieto, {Victor G.} and Raymond, {Austin K.} and Wei Zhang and Trent, {Jonathan C.} and Benjamin, {Robert S.} and Frazier, {Marsha L.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1038/modpathol.2008.46",
language = "English (US)",
volume = "21",
pages = "826--836",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression

AU - Chen, Lei L.

AU - Holden, Joseph A.

AU - Choi, Haesun

AU - Zhu, Jing

AU - Wu, Elsie F.

AU - Jones, Kimberly A.

AU - Ward, John H.

AU - Andtbacka, Robert H.

AU - Randall, R

AU - Scaife, Courtney L.

AU - Hunt, Kelly K.

AU - Prieto, Victor G.

AU - Raymond, Austin K.

AU - Zhang, Wei

AU - Trent, Jonathan C.

AU - Benjamin, Robert S.

AU - Frazier, Marsha L.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Activating mutation in KIT or platelet-derived growth factor-α can lead to gastrointestinal stromal tumors (GISTs). Eighty-four cases from two institutes were analyzed. Of them, 62 (74%) harbored KIT mutations, 7 of which are previously unreported. One exhibited duplication from both intron 11 and exon 11, which has not been reported in KIT in human cancer. A homozygous/hemizygous KIT-activating mutation was found in 9 of the 62 cases (15%). We identified three GIST patients with heterozygous KIT-activating mutations at initial presentation, who later recurred with highly aggressive clinical courses. Molecular analysis at recurrence showed total dominance of homozygous (diploid) KIT-activating mutation within a short period of 6-13 months, suggesting an important role of oncogene homozygosity in tumor progression. Topoisomerase II is active in the S- and G2 phases of cell cycle and is a direct and accurate proliferative indicator. Cellular and molecular analysis of serial tumor specimens obtained from consecutive surgeries or biopsy within the same patient revealed that these clones that acquired the homozygous KIT mutation exhibited an increased mitotic count and a striking fourfold increase in topoisomerase II proliferative index (percentage cells show positive topoisomerase II nuclear staining compared to the heterozygous counterpart within the same patient. KIT forms a homodimer as the initial step in signal transduction and this may account for the quadruple increase in proliferation. Using SNPs for allelotyping on the serial tumor specimens, we demonstrate that the mechanism of the second hit resulting in homozygous KIT-activating mutation and loss of heterozygosity is achieved by mitotic nondisjunction, contrary to the commonly reported mechanism of mitotic recombination.

AB - Activating mutation in KIT or platelet-derived growth factor-α can lead to gastrointestinal stromal tumors (GISTs). Eighty-four cases from two institutes were analyzed. Of them, 62 (74%) harbored KIT mutations, 7 of which are previously unreported. One exhibited duplication from both intron 11 and exon 11, which has not been reported in KIT in human cancer. A homozygous/hemizygous KIT-activating mutation was found in 9 of the 62 cases (15%). We identified three GIST patients with heterozygous KIT-activating mutations at initial presentation, who later recurred with highly aggressive clinical courses. Molecular analysis at recurrence showed total dominance of homozygous (diploid) KIT-activating mutation within a short period of 6-13 months, suggesting an important role of oncogene homozygosity in tumor progression. Topoisomerase II is active in the S- and G2 phases of cell cycle and is a direct and accurate proliferative indicator. Cellular and molecular analysis of serial tumor specimens obtained from consecutive surgeries or biopsy within the same patient revealed that these clones that acquired the homozygous KIT mutation exhibited an increased mitotic count and a striking fourfold increase in topoisomerase II proliferative index (percentage cells show positive topoisomerase II nuclear staining compared to the heterozygous counterpart within the same patient. KIT forms a homodimer as the initial step in signal transduction and this may account for the quadruple increase in proliferation. Using SNPs for allelotyping on the serial tumor specimens, we demonstrate that the mechanism of the second hit resulting in homozygous KIT-activating mutation and loss of heterozygosity is achieved by mitotic nondisjunction, contrary to the commonly reported mechanism of mitotic recombination.

KW - GIST

KW - Homozygous KIT mutation

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=46049097771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46049097771&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2008.46

DO - 10.1038/modpathol.2008.46

M3 - Article

C2 - 18488000

AN - SCOPUS:46049097771

VL - 21

SP - 826

EP - 836

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 7

ER -